• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

Pimavanserin

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease

May 13, 2019

https://clinicaltrials.gov/ct2/show/NCT03947216?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease.

DESCRIPTION:
Condition:   Parkinson Disease
Interventions:   Drug: Active drug: pimavanserin 17mg (2 strength tablets);   Drug: Placebo: 2 tablets containing same excipients except active compound;   Behavioral: Assessment of severity of ICD (impulse control disorders);   Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;   Behavioral: Assessment of quality of life;   Behavioral: Assessment of depression;   Behavioral: Assessment of cognition;   Behavioral: Assessment of severity of Parkinson Disease;   Procedure: Blood analysis;   Procedure: Cardiac monitoring
Sponsor:   University Hospital, Strasbourg, France
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03947216

FIRST POSTED:
Mon, 13 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/13/19 07:43AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03947216?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=04%2F29%2F2019&lupd_d=14&sort=nwst

Powered by Urgent Research

Copyright © 2025 Urgent Research